Satijn; David
Patent Applications and Registrations
Patent applications and USPTO patent grants for Satijn; David.The latest application filed is for "monoclonal antibodies against her2".
Company Profile
41.33.59
- Satijn; David - Utrecht NL
- Satijn; David - Nieuwegein NL
Patent Activity
| Patent | Date |
|---|---|
| Multispecific antibodies against CD40 and CD137 Grant 11,440,966 - Altintas , et al. September 13, 2 | 2022-09-13 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 11,421,024 - Kallunki , et al. August 23, 2 | 2022-08-23 |
| Monoclonal Antibodies Against Her2 App 20220169738 - DE GOEIJ; Bart ; et al. | 2022-06-02 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20220064317 - ALTINTAS; Isil ; et al. | 2022-03-03 |
| Antibodies Grant 11,261,254 - Koopman , et al. March 1, 2 | 2022-03-01 |
| Antibodies App 20220048999 - KOOPMAN; Louise ; et al. | 2022-02-17 |
| Antibodies App 20220049013 - SATIJN; David ; et al. | 2022-02-17 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20220033510 - ALTINTAS; Isil ; et al. | 2022-02-03 |
| Antibody Formulation App 20210369842 - ALTINTAS; Isil ; et al. | 2021-12-02 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20210317225 - ALTINTAS; Isil ; et al. | 2021-10-14 |
| Antibodies Grant 11,130,819 - Satijn , et al. September 28, 2 | 2021-09-28 |
| Antibodies App 20210292418 - KOOPMAN; Louise ; et al. | 2021-09-23 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210277133 - ALTINTAS; Isil ; et al. | 2021-09-09 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210269541 - ALTINTAS; Isil ; et al. | 2021-09-02 |
| Agonistic Tnf Receptor Binding Agents App 20210253725 - Sahin; Ugur ; et al. | 2021-08-19 |
| Monoclonal antibodies against HER2 Grant 11,091,553 - De Goeij , et al. August 17, 2 | 2021-08-17 |
| Methods of producing multispecific antibodies against CD40 and CD137 Grant 11,091,557 - Altintas , et al. August 17, 2 | 2021-08-17 |
| Multispecific antibodies against CD40 and CD137 Grant 11,084,882 - Altintas , et al. August 10, 2 | 2021-08-10 |
| Antibodies App 20210230296 - SATIJN; David ; et al. | 2021-07-29 |
| Monoclonal antibodies against HER2 Grant 11,046,771 - De Goeij , et al. June 29, 2 | 2021-06-29 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210163616 - ALTINTAS; Isil ; et al. | 2021-06-03 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210147522 - KALLUNKI; Pekka ; et al. | 2021-05-20 |
| Antibodies Grant 11,008,399 - Satijn , et al. May 18, 2 | 2021-05-18 |
| Monoclonal Antibodies Against Her2 Epitope App 20210122830 - DE GOEIJ; Bart ; et al. | 2021-04-29 |
| Binding agents binding to PD-L1 and CD137 and use thereof Grant 10,968,280 - Altintas , et al. April 6, 2 | 2021-04-06 |
| Antibodies App 20210070877 - SATIJN; David ; et al. | 2021-03-11 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210061892 - KALLUNKI; Pekka ; et al. | 2021-03-04 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210054057 - KALLUNKI; Pekka ; et al. | 2021-02-25 |
| Agonistic tumor necrosis factor (TNF) receptor binding agents Grant 10,927,181 - Sahin , et al. February 23, 2 | 2021-02-23 |
| Anti-tissue Factor Antibody-drug Conjugates And Their Use In The Treatment Of Cancer App 20210030888 - RANGWALA; Reshma Abdulla ; et al. | 2021-02-04 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20200397913 - BOSHUIZEN; Julia ; et al. | 2020-12-24 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,800,836 - Kallunki , et al. October 13, 2 | 2020-10-13 |
| Monoclonal antibodies against HER2 epitope Grant 10,793,640 - De Goeij , et al. October 6, 2 | 2020-10-06 |
| Antibodies binding AXL Grant 10,765,743 - Breij , et al. Sep | 2020-09-08 |
| Antibodies App 20200277397 - SATIJN; David ; et al. | 2020-09-03 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20200247899 - Kind Code | 2020-08-06 |
| Antibodies Against Pd-l1 App 20200239579 - ALTINTAS; Isil ; et al. | 2020-07-30 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20200199231 - ENGELBERTS; Patrick ; et al. | 2020-06-25 |
| Antibodies Binding Axl App 20200171152 - BREIJ; Esther ; et al. | 2020-06-04 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20200165349 - ALTINTAS; Isil ; et al. | 2020-05-28 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,763 - Kallunki , et al. | 2020-05-12 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,764 - Kallunki , et al. | 2020-05-12 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,640,554 - Kallunki , et al. | 2020-05-05 |
| Agonistic Tnf Receptor Binding Agents App 20200079866 - Sahin; Ugur ; et al. | 2020-03-12 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20200062853 - ALTINTAS; Isil ; et al. | 2020-02-27 |
| Bispecific antibodies against CD3 and CD20 Grant 10,544,220 - Engelberts , et al. Ja | 2020-01-28 |
| Antibodies binding AXL Grant 10,512,688 - Breij , et al. Dec | 2019-12-24 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190382473 - KALLUNKI; Pekka ; et al. | 2019-12-19 |
| Antibodies binding AXL Grant 10,500,276 - Breij , et al. Dec | 2019-12-10 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367595 - Kallunki; Pekka ; et al. | 2019-12-05 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367594 - KALLUNKI; Pekka ; et al. | 2019-12-05 |
| Multispecific Antigen-binding Molecule With Improved Internalization Characteristics App 20190352423 - DE GOEIJ; Bart ; et al. | 2019-11-21 |
| Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains Grant 10,457,735 - Sahin , et al. October 29, 2 | 2019-10-29 |
| Human Antibody Drug Conjugates Against Tissue Factor App 20190315880 - SATIJN; David ; et al. | 2019-10-17 |
| Antibodies Binding Axl App 20190275149 - BREIJ; Esther ; et al. | 2019-09-12 |
| Antibodies for the treatment of synucleinopathy Grant 10,364,285 - Kallunki , et al. | 2019-07-30 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,483 - Kallunki , et al. July 23, 2 | 2019-07-23 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,484 - Kallunki , et al. July 23, 2 | 2019-07-23 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,482 - Kallunki , et al. | 2019-07-23 |
| Anti-death Receptor Antibodies And Methods Of Use Thereof App 20190202926 - BEURSKENS; Frank ; et al. | 2019-07-04 |
| Antibodies Binding Axl App 20190160170 - Breij; Esther ; et al. | 2019-05-30 |
| Antibodies binding AXL Grant 10,201,607 - Breij , et al. Feb | 2019-02-12 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20190022243 - BOSHUIZEN; Julia ; et al. | 2019-01-24 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20180326084 - BOSHUIZEN; Julia ; et al. | 2018-11-15 |
| Antibodies Binding Axl App 20180214549 - BREIJ; Esther ; et al. | 2018-08-02 |
| Monoclonal Antibodies Against Her2 App 20180215827 - DE GOEIJ; Bart ; et al. | 2018-08-02 |
| Monoclonal Antibodies Against Her2 App 20180194845 - DE GOEIJ; Bart ; et al. | 2018-07-12 |
| Agonistic Tnf Receptor Binding Agents App 20180194849 - Sahin; Ugur ; et al. | 2018-07-12 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179271 - Kallunki; Pekka ; et al. | 2018-06-28 |
| Monoclonal Antibodies Against Her2 App 20180179286 - DE GOEIJ; Bart ; et al. | 2018-06-28 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179270 - Kallunki; Pekka ; et al. | 2018-06-28 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127491 - Kallunki; Pekka ; et al. | 2018-05-10 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127492 - Kallunki; Pekka ; et al. | 2018-05-10 |
| Monoclonal Antibodies Against Her2 Epitope App 20180022816 - DE GOEIJ; Bart ; et al. | 2018-01-25 |
| Monoclonal antibodies against HER2 Grant 9,862,769 - De Goeij , et al. January 9, 2 | 2018-01-09 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20170355767 - ENGELBERTS; Patrick ; et al. | 2017-12-14 |
| Monoclonal antibodies against HER2 epitope Grant 9,714,294 - De Goeij , et al. July 25, 2 | 2017-07-25 |
| Antibodies Binding Axl App 20170157250 - BREIJ; Esther ; et al. | 2017-06-08 |
| Human Antibody Drug Conjugates Against Tissue Factor App 20170136130 - SATIJN; David ; et al. | 2017-05-18 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20170015739 - Kallunki; Pekka ; et al. | 2017-01-19 |
| Human antibody drug conjugates against tissue factor Grant 9,492,565 - Satijn , et al. November 15, 2 | 2016-11-15 |
| Human Antibody Drug Conjugates Against Tissue Factor App 20160067349 - SATIJN; David ; et al. | 2016-03-10 |
| Human antibody drug conjugates against tissue factor Grant 9,168,314 - Satijn , et al. October 27, 2 | 2015-10-27 |
| Monoclonal Antibodies Against Her2 App 20130189271 - De Goeij; Bart ; et al. | 2013-07-25 |
| Monoclonal Antibodies Against Her2 Epitope App 20130171148 - De Goeij; Bart ; et al. | 2013-07-04 |
| Human Antibody Drug Conjugates Against Tissue Factor App 20130101608 - Satijn; David ; et al. | 2013-04-25 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 